Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2354 Neoplasms 1704 Prostatic Neoplasms 1192 Lung Neoplasms 922 Colorectal Neoplasms 884 Carcinoma, Non-Small-Cell Lung 866 Leukemia, Myeloid, Acute 593 Pancreatic Neoplasms 574 Multiple Myeloma 551 Carcinoma, Hepatocellular 516 Brain Neoplasms 515 Neoplasm Metastasis 461 Head and Neck Neoplasms 457 Melanoma 414 Ovarian Neoplasms 412 Glioblastoma 402 Precursor Cell Lymphoblastic Leukemia-Lymphoma 398 Stomach Neoplasms 376 Uterine Cervical Neoplasms 362 Squamous Cell Carcinoma of Head and Neck 362 Rectal Neoplasms 342 Recurrence 335 Sarcoma 324 Hematologic Neoplasms 324 Colonic Neoplasms 321 Lymphoma 320 Triple Negative Breast Neoplasms 289 Carcinoma, Renal Cell 283 Urinary Bladder Neoplasms 281 Glioma 280

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Cancer Related Cognitive Decline × 1 year × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡